Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental immune therapy takes on stage IV cancers

NCT ID NCT06296056

Disease control Sponsor: Seoul Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a combination of immune cells in 9 people with stage IV solid tumors that had stopped responding to standard treatments. The main goal was to see if the therapy is safe and to check for any signs that it might control the disease. The study is now complete, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
immune cell therapy
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, focused mainly on safety. The treatment may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

9 people

The number who actually took part.

Started

Aug 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Those who have been histologically or cytologically confirmed as adenocarcinoma among solid tumors * Those with at least one measurable or evaliable lesion by RECIST v1.1 * Those who fail standard treatment for metastatic solid tumors (failure of treatment is defined as failure of not only progression of the disease or recurrence after treatment, but also unacceptable side effects or maintenance of the treatment process) * ECOG performance status 0 or 1 person * A person who can draw about 100 cc of whole blood for the manufacture of immune cells * Weight: More than 50 kg for men and more than 35 kg for women * Hb: 9.0 g/dL or higher (registerable if hemoglobin levels recover to 10.0 g/dL or higher during the screening period); however, transfusions within 7 days prior to screening to meet this standard are not allowed) * Appropriate contraceptive regimen up to 2 months after clinical research drug administration * A person who voluntarily decides to participate after receiving a sufficient explanation for this clinical study and agrees in writing Exclusion Criteria: * Brain Metastasis patients who have symptoms or need treatment \[However, patients with stable brain metastasis who have no symptoms and do not need treatment (excluding anticonvulsants in maintenance therapy) can register\] * A person with a systemic disease that is inappropriate to administer anticancer drugs according to the researcher's judgment * Those with the following cardio-cerebrovascular diseases as of the time of screening * a person who is HIV-positive * Those determined that the researcher was not suitable for participation in this clinical study as a result of the active infection (HBV, HCV) test * a person with acute or severe infection * Those who have autoimmune diseases or have a history of chronic or recurrent autoimmune diseases * Those with a history of organ transplants * a hematopoietic stem cell transplant patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic Solid tumors

Contacts and locations

Locations

  • Seoul Hospital

    Ulaanbaatar, Mongolia

More trials for these conditions

Other studies related to the condition(s) this trial covers.